Immediate Impact
51 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Ryo Ko being referenced
Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR–Mutated Advanced Non–Squamous Non–Small Cell Lung Cancer: The OPAL Study
2023
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ryo Ko | 290 | 378 | 20 | 121 | 58 | 528 | |
| Marta Batus | 290 | 236 | 9 | 176 | 60 | 552 | |
| Shunichiro Iwasawa | 360 | 355 | 13 | 182 | 47 | 637 | |
| Georgia Gomatou | 246 | 250 | 8 | 148 | 33 | 475 | |
| Shinichiro Shimamatsu | 347 | 272 | 20 | 166 | 39 | 564 | |
| Nuria Kotecki | 315 | 276 | 17 | 131 | 66 | 567 | |
| Nathan D. Seligson | 202 | 156 | 14 | 181 | 38 | 502 | |
| Ester Del Signore | 390 | 292 | 20 | 106 | 43 | 539 | |
| Yinyin Qin | 374 | 305 | 24 | 115 | 58 | 607 | |
| Norikazu Matsuo | 416 | 354 | 7 | 89 | 39 | 635 | |
| Zhiguo Luo | 260 | 164 | 11 | 229 | 58 | 541 |
All Works
Login with ORCID to disown or claim papers
Loading papers...